Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium + vilanterol crossover study in COPD with hyperinflation and heart failure
2019-004427-20Phase 4Active
- Sponsor
- Luis Puente Maestu
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) and heart failure (HF) (2 arms), sponsored by Luis Puente Maestu. Primary endpoint: Baseline-corrected time-velocity integral during peak exercise. Started Dec 2019; status: active.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)heart failure (HF)
Beyond the preview
Go deeper on 2019-004427-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004427-20.